PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Investigate And Describe The Treatment Patterns And Effect Of Tofacitinib Indicators For Patients With Rheumatoid Arthritis
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1712
- Registration Number
- NCT04721808
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
- First Posted Date
- 2021-01-25
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 7807
- Registration Number
- NCT04721821
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Korea Post Marketing Surveillance (PMS) Study of Vizimpro
- Conditions
- Lung Neoplasms
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 187
- Registration Number
- NCT04721106
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 42
- Registration Number
- NCT04706793
- Locations
- 🇯🇵
Kojunkai Daido Clinic, Nagoya-shi, Aichi-ken, Japan
🇯🇵Ishii Eye Clinic, Nagareyama-shi, Chiba, Japan
🇯🇵Fukuoka University Hospital, Fukuoka-shi, Fukuoka, Japan
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
- Conditions
- Obesity
- Interventions
- Drug: Placebo (Cohorts 1 and 2)Drug: Placebo (Cohort 3)
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 628
- Registration Number
- NCT04707313
- Locations
- 🇺🇸
PMG Research, Inc. d/b/a PMG Research of Knoxville, Knoxville, Tennessee, United States
🇨🇦Rivergrove Medical Clinic, Winnipeg, Manitoba, Canada
🇨🇦Aggarwal and Associates Limited, Brampton, Ontario, Canada
Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS
- Conditions
- Prader-Willi Syndrome
- Interventions
- Biological: somatropin - GH naïve pediatric cohortBiological: somatropin - GH treated cohortBiological: somatropin - adult cohort
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT04697381
- Locations
- 🇯🇵
Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
🇯🇵Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan
🇯🇵Osaka Women's and Children's Hospital, Izumi, Osaka, Japan
A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 108
- Registration Number
- NCT04682639
- Locations
- 🇺🇸
Mile Square Surgery Center, Fountain Valley, California, United States
🇺🇸Bay Area Chest Physicians, P.A., - Pulmonary Function Test, Clearwater, Florida, United States
🇺🇸Dothan Eyecare - Dr. Brent McKinley (OCT Procedure Only), Dothan, Alabama, United States
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 481
- Registration Number
- NCT04682587
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-05-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107383
- Registration Number
- NCT04681482
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 559
- Registration Number
- NCT04671615
- Locations
- 🇮🇱
Pfizer Pharmaceuticals Israel Ltd., Herzliya Pituach, Israel